ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) was the target of a large growth in short interest in October. As of October 31st, there was short interest totalling 2,160,000 shares, a growth of 5.4% from the October 15th total of 2,050,000 shares. Based on an average trading volume of 310,500 shares, the short-interest ratio is presently 7.0 days.
ANI Pharmaceuticals Stock Down 4.0 %
ANI Pharmaceuticals stock opened at $56.58 on Friday. The business has a fifty day moving average price of $58.40 and a 200-day moving average price of $61.31. ANI Pharmaceuticals has a 1-year low of $48.20 and a 1-year high of $70.81. The stock has a market capitalization of $1.19 billion, a price-to-earnings ratio of -102.87 and a beta of 0.71. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97.
ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last issued its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The business had revenue of $148.30 million for the quarter, compared to analyst estimates of $144.37 million. During the same quarter in the previous year, the firm earned $1.05 earnings per share. The company’s revenue was up 12.5% on a year-over-year basis. Equities research analysts forecast that ANI Pharmaceuticals will post 3.5 EPS for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
ANIP has been the subject of a number of research analyst reports. StockNews.com lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Raymond James upped their price objective on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 18th. Truist Financial increased their target price on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a report on Tuesday, October 22nd. Piper Sandler began coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They issued an “overweight” rating and a $68.00 price target for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $77.33.
Read Our Latest Stock Report on ANIP
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
See Also
- Five stocks we like better than ANI Pharmaceuticals
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- What is the Australian Securities Exchange (ASX)
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- How to Use the MarketBeat Stock Screener
- Time to Load Up on Home Builders?
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.